A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Selegiline (EMSAM)

Monoamine Oxidase Inhibitor class · 4 generic manufacturers · 5 ANDAs filed at FDA.

First FDA approval1996-08-02
Generic availableYes · 4 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$27.9M in CY2024 Part D spend82K claims · 22K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.637/unit
10 NDCs benchmarked, lowest of all strengths.
Average NADAC
$23.06
Across all dosage forms in distribution.
Highest NADAC
$75.41
Wide spread — brand-strength NDCs still in market.
Plans with PA
543 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Selegiline used for?

Selegiline is a Monoamine Oxidase Inhibitor medication tracked in Medicare Part D.

Is there a generic for Selegiline?

Yes. 5 ANDAs filed at FDA, 4 generic manufacturers currently shipping.

How much does my plan pay for Selegiline?

Across 329 Part D plans, Selegiline averages $23.06/unit (NADAC). Lowest available: $0.637/unit. Highest in distribution: $75.41/unit.

Is Selegiline on the FDA shortage list?

No. Selegiline is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Monoamine Oxidase Inhibitor1 alternative in D1
01
Rasagiline
Brand: Azilect
$1.01Lowest NADAC
10Generic mfrs
$42.1MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (9 approvals on file) · NADAC unit costs: CMS NADAC weekly file (10 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.